Verrica Pharmaceuticals Inc.

NASDAQ:VRCA

Biotechnology

Healthcare
$3.14 -0.26%

-$0.02 today

Market cap
$53.94M
Beta
1.49
P/E (TTM)
-3.5
EPS (TTM)
-$1.67
52W Low $3.28High $9.82

Volume 0.10M

Average 0.08M

VRCA Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Verrica Pharmaceuticals Inc.NASDAQ: VRCA

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin widens to -192.8%

Net margin was -192.8% in Q1 FY2026, up 90.5 pp from a year earlier. On a trailing-twelve-month basis it was -48.0%, up 871.2 pp year over year. Over 3 fiscal years it widened by 220.8 pp.

Context

  • Net margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether net margin reaches the consensus estimate from 3 analysts of -90.2% for the fiscal year ending Dec 2026, down from -50.3% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-192.8%-34.2 pp QoQ
Last fiscal yearDec 2025
-50.3%+961.9 pp YoY
LTMMar 2026
-48.0%+871.2 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+90.5 pp-145.6 pp-236.1 pp
1 year+961.9 pp-40.0 pp-1001.8 pp
3 years+220.8 pp+16.1 pp-204.8 pp
5 years+78.6 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
-50.3%
Year-over-year change
+961.9pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How VRCA compares with its peers on the latest reported figures

  • VRCA's LTM Mar 2026 net margin of -48.0% is the lowest of the 2 companies compared; the peer median is 61.9%.
  • Over three fiscal years its change of +220.8 pp compares with a peer median of +699.1 pp.
VRCA Competitors Peer median
Net Margin for VRCA and competitors
Company Period LTM level YoY 3-year change
QTTBQ32 Bio Inc.LTM Mar 202661.9% —+699.1 pp
VRCAVerrica Pharmaceuticals Inc.LTM Mar 2026-48.0% +871.2 pp+220.8 pp
SABSSAB Biotherapeutics, Inc.FY2025— ——
ANTXAN2 Therapeutics, Inc.FY2025— ——
BOLDBoundless Bio, Inc.FY2025— ——
Peer median (excluding VRCA) 61.9%—+699.1 pp

Competitors are the stored peer set for VRCA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue12M9.03M5.12M7.57M35.58M
Cost of Revenue472K725K746K2.74M3.44M
Gross Profit11.53M8.31M4.38M4.83M32.14M
Gross Margin96.1%92.0%85.4%63.8%90.3%
Research & Development15.93M12.2M20.3M11.84M8.86M
Selling, General & Admin26.98M17.41M47.31M58.82M35.22M
Operating Expenses42.44M29.6M70.14M70.75M44.08M
Depreciation & Amortization472K718K836K1.27M781K
EBITDA(30.31M)(21.6M)(62.2M)(65.9M)(9.36M)
EBITDA Margin-252.6%-239.1%-1213.8%-871.0%-26.3%
Operating Income(30.91M)(21.3M)(65.76M)(65.92M)(11.94M)
Operating Margin-257.6%-235.8%-1283.4%-871.3%-33.6%
Interest Income123K476K2.74M1.42M929K
Interest Expense4.3M2.17M3.96M9.41M7.74M
Other Income / Expenses(4.17M)(3.19M)(1.24M)(10.66M)(5.95M)
Income Before Tax(35.08M)(24.49M)(67M)(76.58M)(17.89M)
Pre-Tax Margin-292.3%-271.1%-1307.5%-1012.1%-50.3%
Income Tax Expense00000
Net Income(35.08M)(24.49M)(67M)(76.58M)(17.89M)
Net Margin-292.3%-271.1%-1307.5%-1012.1%-50.3%
EPS (Basic)(12.97)(7.17)(14.78)(14.78)(1.68)
EPS (Diluted)(12.97)(7.17)(14.78)(14.78)(1.68)
Weighted Avg Shares2.7M3.42M4.53M5.18M10.65M
Weighted Avg Shares (Diluted)2.7M3.42M4.53M5.18M10.65M

Verrica Pharmaceuticals Inc.

NASDAQ:VRCA

Intrinsic Alpha fair value

Locked

Current Price

$3.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.